Weight-loss jabs could help minimise asthma symptoms in obese people, according to a study. The drugs should be explored as a ...

Researchers says the drugs could be a treatment for obese people with asthma who are ‘often resistant’ to steroids ...

GLP-1 agonists and dual agonists can cause hypoglycemia, nausea, and more. But there are ways to lessen the side effects, so you can keep taking the medication.

GLP-1 drugs like Ozempic have already become a game-changer for obesity and diabetes. But new research shows they may also ...

Fact checked by Jennifer Klump Injectable GLP-1 drugs like Ozempic and Wegovy are designed for long-term use to manage ...

Roche Holding AG's H2 2025 earnings show solid growth in pharma revenues but highlight pipeline struggles and U.S. pricing pressures. Click for my RHHBY update.

(1276.HK; 600276.SH) delivered a piece of good news for investors with positive trial data for a dual-acting obesity drug ...

GLP-1 drugs for diabetes and weight loss are difficult for some people to inject weekly. A new slow-release gel, tested in rats, could help.

A new study shows that using tirzepatide together with menopause hormone therapy can lead to greater weight loss in postmenopausal women who are overweight or have obesity. These findings were shared ...

GLP-1 drugs have been compared to the discovery of penicillin, which changed the course of medicine by treating several life-threatening illnesses.

GLP-1 blockbusters like semaglutide and tirzepatide are widely used for diabetes and weight loss but come with some nasty ...

For adults with T2D and obesity, GLP-1 RAs are associated with a lower risk for dementia, stroke, and all-cause mortality compared with other antidiabetic drugs.